[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575043":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":42,"responsibleParty":235,"collaborators":26,"id":237,"slug":238,"hasResults":239,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":239,"sex":244,"minAge":245,"maxAge":26,"enrollmentInfo":246,"targetDuration":26,"studyType":249,"phases":250,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":271},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intensive biomarkers-guided arm","EXPERIMENTAL","A second infusion when crosslaps levels reach 300 pg\u002FmL, no later than month-12",[13],"Drug: a second infusion of ZOL when crosslaps levels reach 300 pg\u002FmL",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard treatment arm","ACTIVE_COMPARATOR","Potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome",[19],"Drug: a rescue second infusion at month-12 (standard traitment)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","a second infusion of ZOL when crosslaps levels reach 300 pg\u002FmL","a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg\u002FmL, no later than month-12",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"a rescue second infusion at month-12 (standard traitment)","a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome",[15],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Yannick DEGBOE, MD","CONTACT","05 61 77 73 75","+33","degboe.y@chu-toulouse.fr",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Charline DAGUZAN","05 61 77 84 90","daguzan.c@chu-toulouse.fr",[43,58,69,80,91,102,114,125,136,147,158,169,180,188,199,210,221],{"facility":44,"status":45,"city":46,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Amiens Hospital","RECRUITING","Amiens","France","FR",{"type":50,"coordinates":51},"Point",[52,53],2.3,49.9,{"lat":53,"lon":52},[56],{"name":57,"role":34,"phone":26,"phoneExt":26,"email":26},"Vincent GOEB",{"facility":59,"status":45,"city":60,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Bordeaux Hospital","Bordeaux",{"type":50,"coordinates":62},[63,64],-0.58046,44.84124,{"lat":64,"lon":63},[67],{"name":68,"role":34,"phone":26,"phoneExt":26,"email":26},"Nadia MEHSEN",{"facility":70,"status":45,"city":71,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Cahors Hospital","Cahors",{"type":50,"coordinates":73},[74,75],1.43663,44.4491,{"lat":75,"lon":74},[78],{"name":79,"role":34,"phone":26,"phoneExt":26,"email":26},"Slim LASSOUED",{"facility":81,"status":45,"city":82,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Dax Hospital","Dax",{"type":50,"coordinates":84},[85,86],-1.05366,43.71032,{"lat":86,"lon":85},[89],{"name":90,"role":34,"phone":26,"phoneExt":26,"email":26},"Emilie SHIPLEY",{"facility":92,"status":45,"city":93,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Le Mans Hospital","Le Mans",{"type":50,"coordinates":95},[96,97],0.20251,48.0021,{"lat":97,"lon":96},[100],{"name":101,"role":34,"phone":26,"phoneExt":26,"email":26},"Guillaume DIREZ",{"facility":103,"status":104,"city":105,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Lille Hospital","NOT_YET_RECRUITING","Lille",{"type":50,"coordinates":107},[108,109],3.05512,50.63391,{"lat":109,"lon":108},[112],{"name":113,"role":34,"phone":26,"phoneExt":26,"email":26},"Bernard CORTET",{"facility":115,"status":45,"city":116,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Limoges Hospital","Limoges",{"type":50,"coordinates":118},[119,120],1.24759,45.83362,{"lat":120,"lon":119},[123],{"name":124,"role":34,"phone":26,"phoneExt":26,"email":26},"Anna BILLO",{"facility":126,"status":45,"city":127,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Marseille Hsopital","Marseille",{"type":50,"coordinates":129},[130,131],5.38107,43.29695,{"lat":131,"lon":130},[134],{"name":135,"role":34,"phone":26,"phoneExt":26,"email":26},"Sophie TRIJAU",{"facility":137,"status":45,"city":138,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Montpellier Hospital","Montpellier",{"type":50,"coordinates":140},[141,142],3.87635,43.61093,{"lat":142,"lon":141},[145],{"name":146,"role":34,"phone":26,"phoneExt":26,"email":26},"Paulina SZAFORS",{"facility":148,"status":45,"city":149,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Nice Hospital","Nice",{"type":50,"coordinates":151},[152,153],7.26608,43.70313,{"lat":153,"lon":152},[156],{"name":157,"role":34,"phone":26,"phoneExt":26,"email":26},"Veronique BREUIL",{"facility":159,"status":45,"city":160,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Orléans Hospital","Orléans",{"type":50,"coordinates":162},[163,164],1.90407,47.90248,{"lat":164,"lon":163},[167],{"name":168,"role":34,"phone":26,"phoneExt":26,"email":26},"Eric LESPESSAILLES",{"facility":170,"status":45,"city":171,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Cochin Hospital","Paris",{"type":50,"coordinates":173},[174,175],2.3488,48.85341,{"lat":175,"lon":174},[178],{"name":179,"role":34,"phone":26,"phoneExt":26,"email":26},"Karine BRIOT",{"facility":181,"status":45,"city":171,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":182,"geoPoint":184,"contacts":185},"Lariboisiere Hospital",{"type":50,"coordinates":183},[174,175],{"lat":175,"lon":174},[186],{"name":187,"role":34,"phone":26,"phoneExt":26,"email":26},"Thomas FUNCK-BRENTANO",{"facility":189,"status":45,"city":190,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Poitiers Hospital","Poitiers",{"type":50,"coordinates":192},[193,194],0.34348,46.58261,{"lat":194,"lon":193},[197],{"name":198,"role":34,"phone":26,"phoneExt":26,"email":26},"Guillaume LARID",{"facility":200,"status":45,"city":201,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Rennes Hospital","Rennes",{"type":50,"coordinates":203},[204,205],-1.67431,48.11109,{"lat":205,"lon":204},[208],{"name":209,"role":34,"phone":26,"phoneExt":26,"email":26},"François ROBIN",{"facility":211,"status":45,"city":212,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"Saint Etienne Hospital","Saint-Etienne",{"type":50,"coordinates":214},[215,216],4.39,45.43389,{"lat":216,"lon":215},[219],{"name":220,"role":34,"phone":26,"phoneExt":26,"email":26},"Thierry THOMAS",{"facility":222,"status":45,"city":223,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Toulouse Hospital","Toulouse",{"type":50,"coordinates":225},[226,227],1.44367,43.60426,{"lat":227,"lon":226},[230,232],{"name":231,"role":34,"phone":26,"phoneExt":26,"email":26},"Yannick DEGBOE",{"name":233,"role":234,"phone":26,"phoneExt":26,"email":26},"Anna GOSSET","SUB_INVESTIGATOR",{"type":236,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100575043","phase-4-strategies-for-zoledronic-acid-post-denosumab-discontinuation-in-postmenopausal-osteoporosis-100575043",false,"NCT06767150","StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis","SAFEST","Inclusion Criteria:\n\n* Women with post-menopausal osteoporosis\n* And treated with denosumab for at least 2 years and reaching decision of denosumab withdrawal because of achieved therapeutic target defined as no fracture during treatment; no new risk factors; no BMD decrease \\> 0.03 g\u002Fcm² at the spine or hip;\n* And with a history of severe fracture or a femoral or lumbar T-score ≤ -2.5 prior denosumab initiation.\n\nExclusion Criteria:\n\n* Dmab use for bone disease other than post-menopausal osteoporosis.\n* Uncontrolled endocrine diseases. Liver failure.\n* Use of medication affecting bone metabolism during the last year, including bisphosphonates, teriparatide, romosozumab, Selective Estrogen Receptor Modulators, breast cancer hormonotherapy, glucocorticoids over 5 mg\u002Fday.\n* Contra-indication to bisphosphonates according to license recommendation including chronic kidney disease with GFR stage \\> or = G3b. Prior intolerance to zoledronic acid.\n* Subjects unable to give an informed consent or to fill the case report form. Subjects under law protection.\n* Foreseeable poor compliance with the strategy, alcoholism, toxicomania.","FEMALE","18 Years",{"count":247,"type":248},200,"ESTIMATED","INTERVENTIONAL",[251],"PHASE4","Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.",[254],"Postmenopausal Osteoporosis",[256,257,258,259,260,261],"Postmenopausal osteoporosis","strategy","denosumab","zoledronate","rebound","withdrawal","2025-12-23",{"date":264,"type":265},"2025-12-31","ACTUAL",{"date":267,"type":265},"2025-10-02",{"date":269,"type":248},"2030-10",{"name":5,"class":6},17]